Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

T-cell agonists in cancer immunotherapy

Open access
Choi, Yeonjoo, Shi, Yaoyao, Haymaker, Cara L, Naing, Aung, Ciliberto, Gennaro, Hajjar, Joud · 2020 · Journal for ImmunoTherapy of Cancer

Abstract

Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000966

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Inhibitory and stimulatory receptors on immune cells and cancer cells. APC, antigen-presenting cells; GITR, glucocorticoid-induced tumor necrosis factor receptor; ICOS, inducible T-cell costimulator.
Figure 1 Inhibitory and stimulatory receptors on immune cells and cancer cells. APC, antigen-presenting cells; GITR, glucocorticoid-induced tumor necrosis factor receptor; ICOS, inducible T-cell costimulator.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 119 references

Research works printed but not linked: 2

  1. Massarelli, 2016, Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies, J Immunother Cancer, 4, O7
  2. 10.1111/j.1600-065X.2009.00782.x · DOI · Paper page

Cited by

See all 119

Metadata

Authors
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Istituti di Ricovero e Cura a Carattere Scientifico (IT)
  • Baylor College of Medicine (US)
Corresponding author
Choi, Yeonjoo
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-10
Volume
8
Issue
2
Pages
e000966
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3091714068
Cited by
119
References
119
Citations by year
2026: 6 · 2025: 23 · 2024: 21 · 2023: 26 · 2022: 26 · 2021: 17
FWCI
1.85
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
University of Texas MD Anderson Cancer Center
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
cancer immunotherapy, costimulatory molecules, immune checkpoint inhibitors, 4-1BB, OX40, ICOS, GITR, CD40, antigen-presenting cell activation, T cell activation, combination immunotherapy, radiotherapy, chemotherapy, clinical trials
MeSH terms
Humans, Immunotherapy, Neoplasms, T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T-cell agonists in cancer immunotherapy. https://app.cochat.ai/papers/10.1136/jitc-2020-000966
The paper
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020). T-cell agonists in cancer immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000966

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.